AstraZeneca concludes equity investment in Cellectis
Pharmaceutical Technology
MAY 7, 2024
AstraZeneca has concluded an equity investment in clinical-stage biotechnology company Cellectis following a deal signed in November 2023.
cellectis 
Cellectis files patent for engineered T-cells for immunotherapy with inhibited B2M expression
Pharmaceutical Technology
MARCH 22, 2024
Discover Cellectis SA's groundbreaking patent for engineered T-cells designed for immunotherapy, targeting cancer, infections, and autoimmune diseases. Learn about the innovative method and composition outlined in the patent for effective and affordable treatment.
Engineer 
130
130 Engineer 130
130 Join 32,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
AstraZeneca Invests $140M in Cellectis, Secures 44% Stake in CAR-T Specialist
BioSpace
MAY 6, 2024
Cell and gene therapy company Cellectis announced Monday it has completed a $140 million investment from AstraZeneca that extends the biotech’s cash runway into 2026.
Gene Therapy 101
101 
AstraZeneca and Cellectis partner to advance cell and gene therapies
Pharmaceutical Technology
NOVEMBER 1, 2023
Cellectis will receive $25m in upfront payment, up to $220m in equity investment, and potential milestone based and royalty payments.
Gene Therapy 147
147 
Cellectis to focus on CAR-T cell therapies in 2023
Pharmaceutical Technology
AUGUST 4, 2023
Cellectis provided updates for the three CAR-T cell therapies trials, with the three trials recruiting across various cancer indications.
Trials 130
130 Trials 130
130 
AstraZeneca Drops $245M on Cell and Gene Therapies in Deal with Cellectis
BioSpace
OCTOBER 31, 2023
Cellectis shares skyrocketed over 180% in premarket trading Wednesday. The investment in the French biotech is one of many the pharma giant has made this year to advance cell and gene therapy development.
Gene Therapy 102
102 
AstraZeneca ups stake in Cellectis in latest cell therapy bet
Bio Pharma Dive
MAY 6, 2024
The British drugmaker, which has made genetic medicine a larger priority of late, added $140 million to a deal to develop up to 10 gene and cell therapies.
Genetics 171
171 
Cellectis rockets on gene-editing alliance with AstraZeneca
pharmaphorum
NOVEMBER 1, 2023
Cellectis rockets on gene-editing alliance with AstraZeneca Phil.Taylor Wed, 01/11/2023 - 12:05 Bookmark this
Gene Editing 83
83 
IO360: first allogeneic dual CAR-T shows promise in B-cell Non-Hodgkin lymphoma
Pharmaceutical Technology
MARCH 20, 2024
Cellectis presented promising data with UCART20x22, which represents a pioneering allogeneic dual CAR T-cell product designed to target two established antigens.
Production 130
130 Production 130
130 
Cellectis Announces Participation in Five Investor Conferences
BioTech 365
AUGUST 26, 2021
Cellectis Announces Participation in Five Investor Conferences Cellectis Announces Participation in Five Investor Conferences NEW YORK, Aug. 26, 2021 (GLOBE NEWSWIRE) — Cellectis S.A.
Gene Editing 40
40 
Zenas’ $200m round heads big clutch of bio financings
pharmaphorum
MAY 8, 2024
Our round-up of biotech financings is headed by a $200m round for Zenas, with Cellectis, Reunion, Karius, Context, and Enlaza also raising nine-figure sums
87 
Cellectis Stock Jumps Following Natural Killer Cell Deal with Cytovia
BioSpace
FEBRUARY 15, 2021
Shares of Cellectis Therapeutics were up nearly 10% in premarket trading after the company forged a deal with Cytovia Therapeutics to develop immunotherapies based on gene-edited allogeneic CAR T-cells.
Gene Editing 58
58 
Cellectis Provides Business Objectives for 2022 and Updates its Corporate Presentation
BioTech 365
JANUARY 4, 2022
Cellectis Provides Business Objectives for 2022 and Updates its Corporate Presentation Cellectis Provides Business Objectives for 2022 and Updates its Corporate Presentation NEW YORK, Jan.
40 
Cellectis Announces Launch of Follow-On Offering
BioTech 365
DECEMBER 14, 2020
Cellectis Announces Launch of Follow-On Offering Cellectis Announces Launch of Follow-On Offering NEW YORK, Dec. 14, 2020 (GLOBE NEWSWIRE) — Cellectis S.A.
Development 40
40 Development 40
40 
Cellectis Completes Sale of $47 million through its ATM program
BioTech 365
APRIL 9, 2021
Cellectis Completes Sale of $47 million through its ATM program Cellectis Completes Sale of $47 million through its ATM program NEW YORK, April 09, 2021 (GLOBE NEWSWIRE) — Cellectis S.A. NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) (the “Company”), a clinical-stage … Continue reading →
Sales 40
40 Sales 40
40 
Cellectis Establishes an At-The-Market (ATM) Program on Nasdaq
BioTech 365
MARCH 29, 2021
Cellectis Establishes an At-The-Market (ATM) Program on Nasdaq Cellectis Establishes an At-The-Market (ATM) Program on Nasdaq NEW YORK, March 29, 2021 (GLOBE NEWSWIRE) — Cellectis S.A.
Marketing 40
40 Marketing 40
40 
Cellectis’ Annual Shareholders’ General Meeting to be Held on June 1, 2021
BioTech 365
APRIL 26, 2021
Cellectis’ Annual Shareholders’ General Meeting to be Held on June 1, 2021 Cellectis’ Annual Shareholders’ General Meeting to be Held on June 1, 2021 NEW YORK, April 26, 2021 (GLOBE NEWSWIRE) — Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS). Dear Shareholders, … Continue reading →
40 Cellectis to Hold Third Quarter Earnings Call on Friday, November 5, 2021 at 8AM EDT
BioTech 365
OCTOBER 28, 2021
Cellectis to Hold Third Quarter Earnings Call on Friday, November 5, 2021 at 8AM EDT Cellectis to Hold Third Quarter Earnings Call on Friday, November 5, 2021 at 8AM EDT NEW YORK, Oct. 28, 2021 (GLOBE NEWSWIRE) — Cellectis S.A. … Continue reading →
40 
Cellectis Announces Withdrawal of Follow-On Offering
BioTech 365
DECEMBER 15, 2020
Cellectis Announces Withdrawal of Follow-On Offering Cellectis Announces Withdrawal of Follow-On Offering NEW YORK, Dec.
Gene Editing 40
40 
Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 1, 2021
BioTech 365
JUNE 2, 2021
Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 1, 2021 Cellectis S.A. Reports Results from Annual Shareholders’ General Meeting Held on June 1, 2021 NEW YORK, June 02, 2021 (GLOBE NEWSWIRE) — Cellectis S.A. held its … Continue reading →
40 
Cellectis’ Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical Hold on their Clinical Trials
BioTech 365
JANUARY 10, 2022
Cellectis’ Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical Hold on their Clinical Trials Cellectis’ Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical Hold on their Clinical Trials • Allogene reported that Chromosomal Abnormality Was Not the Result of TALEN® … Continue reading →
Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2021
BioTech 365
NOVEMBER 4, 2021
Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2021 Cellectis Provides Business Update and Reports Financial Results for Third Quarter and First Nine Months 2021 • Sponsored programs at ASH 2021 – preliminary clinical data … Continue reading →
40 
FDA Lifts Hold on Cellectis’ Phase I MELANI-01 Trial After Key Safety Adjustments
BioSpace
NOVEMBER 17, 2020
FDA has lifted a clinical hold on Cellectis’ Phase I MELANI-01 trial evaluating multiple myeloma candidate UCARTCS1 just months after working with the French biopharmaceutical company to adjust its trial protocol to enhance patient safety.
Trials 53
53 Trials 53
53 
Cytovia and Cellectis Expand Their TALEN® Gene-Edited iNK Partnership to Enable Broader Collaboration in China
BioTech 365
NOVEMBER 18, 2021
Cytovia and Cellectis Expand Their TALEN® Gene-Edited iNK Partnership to Enable Broader Collaboration in China Cytovia and Cellectis Expand Their TALEN® Gene-Edited iNK Partnership to Enable Broader Collaboration in China Cytovia Commits to Additional Milestones and Equity grant AVENTURA, Fla.
Gene Editing 40
40 Cellectis to Hold Second Quarter 2021 Earnings Call on Friday, August 6, 2021 at 8AM EDT
BioTech 365
JULY 29, 2021
Cellectis to Hold Second Quarter 2021 Earnings Call on Friday, August 6, 2021 at 8AM EDT Cellectis to Hold Second Quarter 2021 Earnings Call on Friday, August 6, 2021 at 8AM EDT NEW YORK, July 29, 2021 (GLOBE NEWSWIRE) — … Continue reading →
40 
#news #biotech SITC: Cellectis’ off-the-shelf CAR-T for pancreatic cancer and mesothelioma shows activity in mice
BioTech 365
NOVEMBER 12, 2021
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: SITC: Cellectis’ off-the-shelf CAR-T for pancreatic cancer and mesothelioma shows activity in mice.SITC: Cellectis’ off-the-shelf CAR-T for pancreatic cancer and mesothelioma shows activity in mice arlene.weintraub (..)
Research 40
40 Research 40
40 FDA Lifts Clinical Hold on MELANI-01 Study Evaluating Cellectis’ Product Candidate UCARTCS1 in Multiple Myeloma
BioTech 365
NOVEMBER 17, 2020
FDA Lifts Clinical Hold on MELANI-01 Study Evaluating Cellectis’ Product Candidate UCARTCS1 in Multiple Myeloma FDA Lifts Clinical Hold on MELANI-01 Study Evaluating Cellectis’ Product Candidate UCARTCS1 in Multiple Myeloma NEW YORK, Nov. 17, 2020 (GLOBE NEWSWIRE) — Cellectis (Euronext … Continue reading →
Production 40
40 Production 40
40 
#news #biotech Cellectis and Cytovia in US$760m licence deal
BioTech 365
FEBRUARY 16, 2021
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Cellectis and Cytovia in US$760m licence deal. from European Biotechnology – first and foremost in European biotech [link].
Research 40
40 Research 40
40 
#news #biotech Cellectis and Cynovia in US$760m licence deal
BioTech 365
FEBRUARY 16, 2021
Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Cellectis and Cynovia in US$760m licence deal. from European Biotechnology – first and foremost in European biotech [link].
Research 40
40 Research 40
40 
Cellectis to Present Preclinical Data on UCARTMESO Supporting Anti-Tumor Activity at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
BioTech 365
OCTOBER 12, 2021
Cellectis to Present Preclinical Data on UCARTMESO Supporting Anti-Tumor Activity at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting Cellectis to Present Preclinical Data on UCARTMESO Supporting Anti-Tumor Activity at the Society for Immunotherapy of Cancer (SITC) 36th … Continue reading →
40 Cellectis organise une conférence téléphonique pour présenter ses résultats financiers du deuxième trimestre 2021 le vendredi 6 août à 14h00 CET
BioTech 365
JULY 29, 2021
Cellectis organise une conférence téléphonique pour présenter ses résultats financiers du deuxième trimestre 2021 le vendredi 6 août à 14h00 CET Cellectis organise une conférence téléphonique pour présenter ses résultats financiers du deuxième trimestre 2021 le vendredi 6 août à … Continue reading →
40 Cellectis Presents Initial Preclinical Data on Two Novel Gene Therapies for Patients with RAG1 Severe Combined Immunodeficiency (SCID) and Hyper IgE syndrome at ESGCT 2021
BioTech 365
OCTOBER 19, 2021
Cellectis Presents Initial Preclinical Data on Two Novel Gene Therapies for Patients with RAG1 Severe Combined Immunodeficiency (SCID) and Hyper IgE syndrome at ESGCT 2021 Cellectis Presents Initial Preclinical Data on Two Novel Gene Therapies for Patients with RAG1 Severe Combined Immunodeficiency … Continue reading →
Gene Therapy 40
40 
Cellectis Reports Encouraging Clinical Data from BALLI-01 Study in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, and Preclinical Data from TALGlobin01 at the 63rd American Society of Hematology Annual Meeting
BioTech 365
DECEMBER 11, 2021
Cellectis Reports Encouraging Clinical Data from BALLI-01 Study in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, and Preclinical Data from TALGlobin01 at the 63rd American Society of Hematology Annual Meeting Cellectis Reports Encouraging Clinical Data from BALLI-01 Study in Relapsed/Refractory B-cell Acute Lymphoblastic … Continue (..)
40 
Cellectis Reports Preliminary Results from its Phase 1 BALLI-01 Study of UCART22 in R/R Adult B-ALL at American Society of Hematology (ASH) Annual Meeting
BioTech 365
DECEMBER 5, 2020
Cellectis Reports Preliminary Results from its Phase 1 BALLI-01 Study of UCART22 in R/R Adult B-ALL at American Society of Hematology (ASH) Annual Meeting Cellectis Reports Preliminary Results from its Phase 1 BALLI-01 Study of UCART22 in R/R Adult B-ALL … Continue reading →
40 
Next Gen CAR T Cell could Enable Large-Scale Deployment Against Cancer
BioSpace
JUNE 29, 2022
???????Cellectis shared how its novel immune-evasive universal CAR T cells may potentially deploy large amounts of T-cell product candidates to target multiple malignancies.
Production 98
98 Production 98
98 
Innovation in immuno-oncology: Leading companies in in-vitro T-cell activation
Pharmaceutical Technology
MARCH 9, 2023
Bristol-Myers Squibb and Cellectis are the other key patent filers in in-vitro T-cell activation. In 2022, Immatics and Editas Medicine entered a research collaboration and licensing agreement to combine gamma-delta T-cell adoptive cell therapies and gene editing to develop medicines for the treatment of cancer.
In-Vitro 130
130 
Innovation in immuno-oncology: Leading companies in T-cell culturing
Pharmaceutical Technology
JUNE 4, 2023
Patent volumes related to T-cell culturing Company Total patents (2010 - 2021) Premium intelligence on the world's largest companies Immatics 651 Unlock company profile Johnson & Johnson 499 Unlock company profile Bristol-Myers Squibb 316 Unlock company profile Iovance Biotherapeutics 275 Unlock company profile OncoTherapy Science 205 Unlock company (..)
Antibody 130
130 
Leading innovators in lipase compositions for the pharmaceutical industry
Pharmaceutical Technology
APRIL 18, 2023
Patent volumes related to lipase compositions Company Total patents (2010 - 2021) Premium intelligence on the world's largest companies Novo Nordisk Foundation 340 Unlock company profile Sangamo Therapeutics 164 Unlock company profile Corteva 147 Unlock company profile Royal DSM 129 Unlock company profile E.
Cosmetics 130
130 
Servier beefs up in cancer, buying Agios’ oncology business for $1.8bn
pharmaphorum
DECEMBER 23, 2020
This year it’s also doubled down on an alliance with off-the-shelf CAR-T specialist Cellectis , and bought Danish cancer biotech Symphogen. The Agios deal comes just a day after Servier announced a strategic alliance with Celsius Therapeutics to find new drug targets for colorectal cancer.
Marketing 98
98 
Leading innovators in zinc-finger nucleases for the pharmaceutical industry
Pharmaceutical Technology
MAY 8, 2023
Patent volumes related to zinc-finger nucleases Company Total patents (2010 - 2021) Premium intelligence on the world's largest companies Sangamo Therapeutics 793 Unlock company profile E.
Genetics 130
130 Allogene set to disrupt CAR-T market with pivotal trial of ‘off the shelf’ therapy
pharmaphorum
MAY 21, 2021
” Led by former Kite execs Arie Belldegrun and David Chang, Allogene partnered with French firms Cellectis and Servier to develop allogeneic CAR-Ts, after buying out Pfizer and taking over its role in an R&D collaboration.
Marketing 53
53 
Recon: FDA approves Heron’s non-opioid anesthetic; Poll suggests low public trust in US health insti
The Pharma Data
MAY 13, 2021
Sanofi, Cellectis team up to pair Lemtrada with allogeneic CAR-Ts; Bristol Myers joins Evotec’s drive to advance UK science ( Endpoints ). . ‘Imminent’ Generic Approvals Expected To Help US FDA Meet On-Time Review Metric Retroactively ( Pink Sheet ).
FDA Approval 52
52 
Europe: Where is the drug discovery innovation?
Drug Discovery World
MAY 6, 2024
Biotechs such as ourselves and Owkin are leveraging artificial intelligence.” Basel: The home of big pharma No overview of cities for drug discovery in Europe can overlook Basel.
Drugs 59
59 
Leading innovators in transcription factors for AAV for the pharmaceutical industry
Pharmaceutical Technology
JUNE 4, 2023
Jude Children’s Research Hospital 29 Unlock company profile Fondazione Telethon 27 Unlock company profile UniQure 26 Unlock company profile Eyeserv 26 Unlock company profile Pfizer 25 Unlock company profile Adverum Biotechnologies 23 Unlock company profile Massachusetts Eye and Ear Infirmary 22 Unlock company profile Bayer 21 Unlock company profile (..)
Gene 262
262 
Let's personalize your content